

September 26, 2012

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL:

USAN (ZZ-93)	IMILECLEUCEL-T
PRONUNCIATION	im" i lek loo' sel - tee
THERAPEUTIC CLAIM	Cellular immunotherapy for the treatment of multiple sclerosis

DESCRIPTION

This product consists of attenuated autologous myelin peptide-reactive T cells from three myelin antigens. Patient-specific autoreactive T-cells are identified and enriched. Lymphocytes and monocytes from whole blood collection serve as the source for the product.

SPONSOR	Opexa
TRADEMARK	Tcelna™
TRIVIAL NAME	T-cell immunotherapy

SCS